ArticleJournal of cachexia, sarcopenia and muscle2022
Is age-related sarcopenia a real concern for my developing country?
Article in Journal of cachexia, sarcopenia and muscle, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Development and validation of nomogram and machine learning models to predict sarcopenia in patients with chronic kidney disease.Scientific reports · 2025Article
- Bioinformatics and machine learning approaches to explore key biomarkers in muscle aging linked to adipogenesis.BMC musculoskeletal disorders · 2025Article
- Exploring the impact of vitamin D-related genetic variants on muscular fitness changes in middle-aged and older adults in Kosovo.Frontiers in public health · 2025Article
- Prospects for the diagnosis and treatment of sarcopenia in the Philippines.Frontiers in medicine · 2024Review
- Effects of household solid fuel use on sarcopenia in middle-aged and older adults: evidence from a nationwide cohort study.Frontiers in public health · 2024Article
- Diagnosing sarcopenia in clinical practice: international guidelines vs. population-specific cutoff criteria.Frontiers in medicine · 2024Article
- Association between persistent musculoskeletal pain and incident sarcopenia in China: the mediating effect of depressive symptoms.Frontiers in public health · 2024Article
- Knowledge, attitude, and practice regarding sarcopenia: a survey between orthopedic and geriatric professionals in China.Aging clinical and experimental research · 2023Article
- The association of dietary inflammatory potential with sarcopenia in Chinese community-dwelling older adults.BMC geriatrics · 2023Article
- Is age-related sarcopenia a real concern for my developing country?Journal of cachexia, sarcopenia and muscle · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ageing is a distinctive feature of living organisms. With the modernization of human societies, including the development of science, technology and education, expected life expectancy at birth is being extended. This allows novel health-related conditions to gain particular interest amongst the field experts. Along comes sarcopenia, an age-related condition of global proportions that effects all populations, societies and countries. Several international working groups have been trying to identify the more appropriate and applicable sarcopenia definition and diagnostic criteria to follow. Contrary to the initial muscle mass-related context, the shift of attention to muscle strength by the revised European Working Group in Sarcopenia for Older People (EWGSOP2) was ground-breaking and potentially game-changing. The suggested diagnostic algorithm by the EWGSOP2 for case finding, diagnosing and quantifying the severity of cases further facilitated the applicability on clinical practices. Since being directly related to the ageing process, sarcopenia presents an issue of growing concern particularly within the high-income and developed world regions that are generally characterized with an increased life expectancy. In contrast, the developing world and their generally lower life expectancy do not always have sarcopenia amongst the top targeted health-related concerns. In such cases, the expected life expectancy and the populations' quality of life do not necessarily present an issue of major interest. Other serious medical concerns of acute state often eclipse the need for long-term health-related investments, shifting the interest towards only direct interventions and short-term planning. In conclusion, the emerging of sarcopenia as a serious age-related concern is finding care providers and healthcare systems from lower and middle-income countries (LMICs) unprepared. For the time being, it needs to be introduced and promoted in the developing world as a condition with direct life-threatening implications. Simple and creative forms of approach should be ideated and implemented in both scientific and clinical contexts (by researchers and care providers, respectively). The best practice to address this situation would be by empowering intradisciplinary and interdisciplinary collaborations, as well as facilitating interconnections between researches, healthcare practitioners and clients. This should help establish sarcopenia as a serious age-related condition that needs a multidisciplinary and multidimensional approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.